B
Beacon Biosignals
AI-driven EEG biomarkers for brain health
About Beacon Biosignals
Beacon Biosignals is a Boston-based neurotechnology company that applies machine learning to electroencephalography (EEG) and sleep data to produce quantitative biomarkers of brain function. The company was founded in 2019 by physician-scientists and engineers from Harvard and MIT, and it focuses on neurological, psychiatric and sleep disorders, areas where objective clinical measures have historically been scarce.
The company's core offering, the Beacon Platform, combines a large clinical EEG database with proprietary algorithms that detect features such as epileptiform activity, sleep architecture and other electrophysiological signatures. Data are collected in patients' homes using FDA-cleared wearable devices, including the Waveband headband, which records brain activity during sleep and wake, alongside home sleep-testing hardware that measures airflow, respiratory effort and blood oxygen saturation.
Beacon's main customers are biopharmaceutical and biotechnology companies developing therapies for the central nervous system. They use the platform for patient selection, pharmacokinetic and pharmacodynamic studies, dose finding and quantitative clinical trial endpoints in conditions such as Alzheimer's disease, Parkinson's disease, epilepsy, narcolepsy, depression and sleep apnea. The company also works with academic medical centers and develops AI-assisted diagnostic tools intended for clinical use.
Beyond trial services, Beacon is building a foundation model of brain activity trained on millions of hours of EEG recordings, with the aim of identifying early disease signatures and predicting how individual patients respond to treatment.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 131
- Open positions
- 5
- Dealroom signal
- 93.5/100
- Industry
- Health
- Sub-industry
- BioTechnology, Health Platform
- Sector
- Biotechnology, Drug Development, Neurology, Core AI, Precision Medicine, Techbio, Hard Tech
- Technology
- Artificial Intelligence, Deep Tech
- Business model
- SaaS
- Client focus
- B2B
- Investment activity
- 1 company, latest Jul 2023
- Capital deployed
- —
- Preferred round
- ACQUISITION
News
Open roles
| Role | Team | Location | Posted |
|---|---|---|---|
| Marketing CoordinatorMarketing | Marketing | Boston, MA / Remote | 2d ago |
| Director, Alliance Management | New York, NY | 2d ago | |
| Quality EngineerEngineering | Engineering | Boston, MA / Remote | 2d ago |
| Senior Mobile App Engineer (React Native)Engineering | Engineering | Boston, MA / Remote | 4d ago |
| Business Development AssociateSales | Sales | Boston, MA / Remote | 6d ago |
| Logistics & Distribution ManagerOperations | Operations | Boston, MA / Remote | 6d ago |
| Senior Algorithm EngineerEngineering | Engineering | Boston, MA / Remote | 1w ago |
| Clinical Study Operations AssociateClinical | Clinical | Remote | 1w ago |
| Senior IT SpecialistEngineering | Engineering | Boston, MA / Remote | 1w ago |
| Fulfillment Automation Solutions EngineerCustomer | Customer | Boston, MA / Remote | 1w ago |
| Logistics & Demand Planning DirectorOperations | Operations | Boston, MA / Remote | 3w ago |
| Hardware Test EngineerEngineering | Engineering | Boston, MA | 3w ago |
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Apr 2026 | $11M | $430M | Palo Santo Venture Fund · Samsung Next · Kicker Ventures · JSL Health Capital | ↗ |
| SERIES BOther financing | Nov 2025 | $86M | $344M | General Catalyst · GV · Casdin Capital · Indicator Ventures | ↗ |
Growth signals
Latest recorded traffic for Beacon Biosignals is 19K monthly website visits, up 58.3% over the last three months. Beacon Biosignals's team grew 21.3% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Beacon Biosignals in the Boston ecosystem
The Beacon Biosignals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A15 investors entered at this stage
General Catalyst
Casdin Capital
Indicator Ventures
Half Court VC
GV
Takeda
Section 32
Innoviva
Logos Capital
Catalio Capital Management
Nexus NeuroTech Ventures
Palo Santo Venture Fund
Samsung Next
Kicker Ventures
JSL Health Capital
Source: Dealroom Talent Intelligence.
See Beacon Biosignals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









